News

BlinkRx Partners with ARS Pharmaceuticals for neffy® Launch

BlinkRx Partners with ARS Pharmaceuticals for neffy® Launch

BlinkRx Collaborates with ARS Pharmaceuticals to Introduce neffy®

BlinkRx, a pioneering patient access platform, has recently joined forces with ARS Pharmaceuticals to enhance patient care with the introduction of neffy®, an innovative needle-free epinephrine nasal spray. This groundbreaking treatment represents a significant advancement in the management of Type I allergic reactions, including life-threatening anaphylaxis.

Unveiling the Advantages of neffy®

neffy® is unique as the first and only needle-free treatment developed for those experiencing severe allergic reactions. It is specifically designed for individuals weighing 30 kgs (66 lbs) or more, making it a versatile option for both children and adults. Patients prescribed neffy® can now easily access this medication via the BlinkRx platform, which prioritizes transparent pricing, free home delivery, and personalized support for each patient's needs.

Understanding the Impact of Allergy Reactions

In the United States, around 40 million individuals suffer from Type I allergic reactions caused by various triggers, including food allergies and insect venom. Despite this alarming number, only a fraction—about 3.3 million—fill prescriptions for epinephrine devices annually, and less than half consistently carry the devices in emergencies. Concerningly, Type I allergic reactions contribute to up to 500,000 emergency room visits each year.

Addressing Critical Needs with Innovative Solutions

By providing neffy®, BlinkRx aims to reduce the barriers to treatment during critical moments when prompt action is necessary. The user-friendly design of neffy® allows caregivers and patients to respond effectively in emergencies, thereby increasing the likelihood of timely administration of epinephrine.

Quotes from Key Executives

Richard Lowenthal, CEO and President of ARS Pharmaceuticals, shares his enthusiasm, stating, "We’re thrilled to make neffy® available through BlinkRx so people with severe allergic reactions can have a needle-free option for treating symptoms of anaphylaxis." He further emphasizes the partnership: "Through neffyConnect and in collaboration with BlinkRx, eligible commercially insured patients can obtain two neffy® devices at a co-pay of $25. For those without insurance or with plans that exclude neffy®, we are pleased to offer a cash price of $199."

Geoffrey Chaiken, CEO of Blink Health, expressed his commitment to patient access, noting, "At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. Making neffy® available on our platform enhances the accessibility of epinephrine for patients in need, particularly for underserved communities."

About BlinkRx and Its Revolutionary Approach

BlinkRx is at the forefront of reshaping the pharmacy experience by leveraging advanced technology to greatly improve patient access to branded medications. The company provides healthcare providers with dedicated access teams and comprehensive authorization support to facilitate patient care. In addition, patients benefit from affordable and transparent pricing, co-pay assistance, free home delivery options, and dedicated support tailored to individual needs.

Learn More

To discover more about the services offered by BlinkRx and the benefits of using their platform to access healthcare solutions, visit their official website and view their resources designed for both patients and healthcare professionals.

Frequently Asked Questions

What is neffy®?

neffy® is a needle-free epinephrine nasal spray designed for treating severe allergic reactions, including anaphylaxis.

Who can use neffy®?

neffy® is available for patients who weigh 30 kgs (66 lbs) or more, applicable for both children and adults.

How does BlinkRx facilitate access to neffy®?

BlinkRx allows patients to access neffy® with transparent pricing, free home delivery, and personalized support.

What partnerships support the launch of neffy®?

BlinkRx has partnered with ARS Pharmaceuticals to provide neffy® efficiently through its platform.

What are the financial options available for neffy®?

Insured patients may pay a co-pay of $25 for neffy®, while non-insured patients can access it for a cash price of $199.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Smart Cooling Accessory: A Game Changer for AC Units?

Updated Category News Views 0

New Kid on the Block: The Smart Cooling Game They say the devil's in the details, and this one’s got all the right tweaks. Picture this — a compressor-based air conditioning system beefing up with a savvy accessory that promises to give your condenser coil some extra muscle. That's right, we've got ourselves a new contender in the cooling corner: THE CSC UNIT. It's...

Continue Reading
Nutex Health Scores Top Workplace Honor in 2026

Updated Category News Views 105

Nutex Health: Accolades and Aspirations Nutex Health just snagged something pretty noteworthy: They've been crowned a 2026 Houston Top Workplace by the Houston Chronicle. Now, before you start throwing confetti, let's chew on what this really means. It's no small potatoes, folks. We're talking employee respect and satisfaction measured by Energage’s surveys. It's proof...

Continue Reading
CHARMANT Eyewear Fuses Fashion and Functionality

Updated Category News Views 54

Eyewear ain’t just about seeing clearly anymore—it’s fashion with a capital ‘F’. The CHARMANT Japanese Made brand decided to foist this idea upon the world, putting their money where your eyeballs are, by injecting a dose of trendy glam into what they already do so well: comfort. Fusion of Style and Comfort Catch this: CHARMANT hit the global stage back in June...

Continue Reading
Human Development Fund's Bold Partnership for Growth

Updated Category News Views 54

An Unusual Alliance with Far-Reaching Implications Every once in a while, a nonprofit steps up with a move that makes even the toughest investors take notice. This isn't some Wall Street ticker talk, sure, but it’s worth turning your chair toward the table. The Human Development Fund (HDF) has penned a strategic deal with the Islamic Development Bank (IsDB), putting its...

Continue Reading
Millrose Faces Class Action Over Misleading Investors

Updated Category News Views 6

Millrose Properties Steps Into Legal Hot Water Ah, stocks and legal squabbles—a pairing as old as Wall Street itself. Now, folks, it seems Millrose Properties, Inc. has stepped right onto the chopping block with a lawsuit knocking on their door over claims they misled investors. The suits from the DJS Law Group aren't mince words: we're talking alleged violations of the...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 217

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Xinjiang Women Embrace New Horizons in Tianshan Peaks

Updated Category News Views 89

Scaling New Heights in Xinjiang Up there on the Tianshan Mountains, looking past those towering cliffs, what catches the eye isn't just breathtaking views but rising opportunities. In the land of Xinjiang, far from the bustling metropolises, young women are finding platforms to not just exist but to thrive. City by city, the narrative is changing as these women carve...

Continue Reading
Stocks Jump Ahead of Critical Inflation Reports

Updated Category News Views 41

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 164

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
Vinamilk's Optimum Gold Shines at Global Awards

Updated Category News Views 49

A Win Beyond Borders: Vinamilk's Global Recognition Sometimes, you gotta hand it to the underdog who comes out swinging and bags the big trophy. This time, it's Vinamilk's Optimum Gold nabbing the "Brand of the Year" at the World Branding Awards 2026-2027. Kicking open international doors from a quaint start in Vietnam to now shining under London's glittery skyline,...

Continue Reading

Top 5 Most Recently Viewed Articles

TGS ASA Engages Fixed Income Investors for Key Meetings

Updated Category News Views 137

TGS ASA Engages in Important Fixed Income Investor Meetings Oslo, Norway – TGS ASA, a pioneering force in energy data and intelligence, is preparing to engage with fixed income investors over a series of meetings. Scheduled to commence on a Monday, these meetings will see participation from notable institutions including J.P. Morgan, Danske Bank, and DNB Markets,...

Continue Reading
Man Group PLC's Disclosure on Urban Logistics REIT plc Holdings

Updated Category News Views 135

Understanding Man Group PLC's Recent Disclosure In the world of finance, transparency is key. This recent announcement from Man Group PLC serves as a public opening position disclosure concerning Urban Logistics REIT plc. It highlights the interests and positions held by a person in the relevant securities that are 1% or greater, adhering to Rule 8.3 of the Takeover Code....

Continue Reading
Understanding the Shift in Employer Attitudes Towards Talent

Updated Category News Views 221

Understanding the Shift in Employer Attitudes Towards Talent A recent survey unveiled significant insights into hiring practices and employer attitudes regarding overqualified candidates. Employers often welcome these candidates, yet they harbor deep concerns about retention and engagement, which leaves many job seekers feeling anxious. This changing perspective...

Continue Reading
GeneDx Reports Q4 Earnings: Analysts React with Price Cuts

Updated Category News Views 218

Unpacking the Earnings Surprise Can’t say I didn’t see that one coming. GeneDx (NASDAQ:WGS) drops some profits like it’s hot for Q4, clocking in earnings of 14 cents per share. That’s a solid beat compared to the 11-cent consensus the suits on Wall Street were whispering about. You can’t shake a stick at that, right? Well, not so fast—because the stock took a...

Continue Reading
Investing in Freeport-McMoRan: A 10-Year Perspective

Updated Category News Views 197

A Deep Dive into Freeport-McMoRan's Journey Alright, let’s cut to the chase. Freeport-McMoRan (NYSE: FCX)—this name's been buzzing on the trading floor for a while now. If you had put down $100 in FCX stock a decade ago, buckle up—your investment would be sitting pretty at about $859.11 today. That’s quite the leap, huh? In a market that shifts gears faster than a...

Continue Reading